EcoDrugPlus


Keyword(s):	Human Metabolites
Molecule Category	Free-form
EPA CompTox	DTXSID90952428

Keyword(s):

Human Metabolites

Molecule Category

Free-form

EPA CompTox

DTXSID90952428


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	RCMRLMJSJGLGEU-UHFFFAOYSA-N
Smiles	CCOC(=O)C(C)[P+](c1ccccc1)(c1ccccc1)c1ccccc1
InChI	InChI=1S/C23H24O2P/c1-3-25-23(24)19(2)26(20-13-7-4-8-14-20,21-15-9-5-10-16-21)22-17-11-6-12-18-22/h4-19H,3H2,1-2H3/q+1

InChI Key

RCMRLMJSJGLGEU-UHFFFAOYSA-N

Smiles

CCOC(=O)C(C)[P+](c1ccccc1)(c1ccccc1)c1ccccc1

InChI

InChI=1S/C23H24O2P/c1-3-25-23(24)19(2)26(20-13-7-4-8-14-20,21-15-9-5-10-16-21)22-17-11-6-12-18-22/h4-19H,3H2,1-2H3/q+1

Property Name	Value
Molecular Formula	C23H24O2P1
Molecular Weight	363.15
AlogP	3.93
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	26.3
Molecular species	None
Aromatic Rings	3.0
Heavy Atoms	26.0

Property Name

Value

Molecular Formula

C23H24O2P1

Molecular Weight

363.15

AlogP

3.93

Hydrogen Bond Acceptor

2.0

Hydrogen Bond Donor

0.0

Number of Rotational Bond

6.0

Polar Surface Area

26.3

Molecular species

None

Aromatic Rings

3.0

Heavy Atoms

26.0

Resources	Reference
CAS NUMBER	30018-16-7
NORMAN SUSDAT
PubChem	87674
ChemSpider	79096.0

Resources

Reference

CAS NUMBER

30018-16-7

NORMAN SUSDAT

PubChem

87674

ChemSpider

79096.0


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

(1-ETHOXY-1-OXOPROPAN-2-YL)(TRIPHENYL)PHOSPHANIUM BROMIDE

Structure

Physicochemical Descriptors

Cross References